194 related articles for article (PubMed ID: 11291041)
1. Interleukin-13 receptor as a unique target for anti-glioblastoma therapy.
Husain SR; Joshi BH; Puri RK
Int J Cancer; 2001 Apr; 92(2):168-75. PubMed ID: 11291041
[TBL] [Abstract][Full Text] [Related]
2. Interleukin-13 fusion cytotoxin as a potent targeted agent for AIDS-Kaposi's sarcoma xenograft.
Husain SR; Puri RK
Blood; 2000 Jun; 95(11):3506-13. PubMed ID: 10828036
[TBL] [Abstract][Full Text] [Related]
3. Interleukin-13 receptor-directed cytotoxin for malignant glioma therapy: from bench to bedside.
Husain SR; Puri RK
J Neurooncol; 2003 Oct; 65(1):37-48. PubMed ID: 14649884
[TBL] [Abstract][Full Text] [Related]
4. Interleukin-13 receptor-targeted cancer therapy in an immunodeficient animal model of human head and neck cancer.
Kawakami K; Kawakami M; Joshi BH; Puri RK
Cancer Res; 2001 Aug; 61(16):6194-200. PubMed ID: 11507072
[TBL] [Abstract][Full Text] [Related]
5. Complete regression of established human glioblastoma tumor xenograft by interleukin-4 toxin therapy.
Husain SR; Behari N; Kreitman RJ; Pastan I; Puri RK
Cancer Res; 1998 Aug; 58(16):3649-53. PubMed ID: 9721874
[TBL] [Abstract][Full Text] [Related]
6. Targeting of interleukin-13 receptor on human renal cell carcinoma cells by a recombinant chimeric protein composed of interleukin-13 and a truncated form of Pseudomonas exotoxin A (PE38QQR).
Puri RK; Leland P; Obiri NI; Husain SR; Kreitman RJ; Haas GP; Pastan I; Debinski W
Blood; 1996 May; 87(10):4333-9. PubMed ID: 8639793
[TBL] [Abstract][Full Text] [Related]
7. Heterogeneity in interleukin-13 receptor expression and subunit structure in squamous cell carcinoma of head and neck: differential sensitivity to chimeric fusion proteins comprised of interleukin-13 and a mutated form of Pseudomonas exotoxin.
Joshi BH; Kawakami K; Leland P; Puri RK
Clin Cancer Res; 2002 Jun; 8(6):1948-56. PubMed ID: 12060640
[TBL] [Abstract][Full Text] [Related]
8. Improved anti-tumor activity and safety of interleukin-13 receptor targeted cytotoxin by systemic continuous administration in head and neck cancer xenograft model.
Kawakami K; Husain SR; Kawakami M; Puri RK
Mol Med; 2002 Aug; 8(8):487-94. PubMed ID: 12435859
[TBL] [Abstract][Full Text] [Related]
9. Specifically targeted killing of interleukin-13 (IL-13) receptor-expressing breast cancer by IL-13 fusion cytotoxin in animal model of human disease.
Kawakami K; Kawakami M; Puri RK
Mol Cancer Ther; 2004 Feb; 3(2):137-47. PubMed ID: 14985454
[TBL] [Abstract][Full Text] [Related]
10. Cintredekin besudotox in treatment of malignant glioma.
Mut M; Sherman JH; Shaffrey ME; Schiff D
Expert Opin Biol Ther; 2008 Jun; 8(6):805-12. PubMed ID: 18476792
[TBL] [Abstract][Full Text] [Related]
11. Human glioma cells overexpress receptors for interleukin 13 and are extremely sensitive to a novel chimeric protein composed of interleukin 13 and pseudomonas exotoxin.
Debinski W; Obiri NI; Powers SK; Pastan I; Puri RK
Clin Cancer Res; 1995 Nov; 1(11):1253-8. PubMed ID: 9815919
[TBL] [Abstract][Full Text] [Related]
12. Analysis of antitumor activity of an interleukin-13 (IL-13) receptor-targeted cytotoxin composed of IL-13 antagonist and Pseudomonas exotoxin.
Kioi M; Kawakami K; Puri RK
Clin Cancer Res; 2004 Sep; 10(18 Pt 1):6231-8. PubMed ID: 15448012
[TBL] [Abstract][Full Text] [Related]
13. Analysis of target genes induced by IL-13 cytotoxin in human glioblastoma cells.
Han J; Yang L; Puri RK
J Neurooncol; 2005 Mar; 72(1):35-46. PubMed ID: 15803373
[TBL] [Abstract][Full Text] [Related]
14. Convection-enhanced delivery of interleukin-13 receptor-directed cytotoxin for malignant glioma therapy.
Kioi M; Husain SR; Croteau D; Kunwar S; Puri RK
Technol Cancer Res Treat; 2006 Jun; 5(3):239-50. PubMed ID: 16700620
[TBL] [Abstract][Full Text] [Related]
15. Receptor for interleukin (IL) 13 does not interact with IL4 but receptor for IL4 interacts with IL13 on human glioma cells.
Debinski W; Miner R; Leland P; Obiri NI; Puri RK
J Biol Chem; 1996 Sep; 271(37):22428-33. PubMed ID: 8798406
[TBL] [Abstract][Full Text] [Related]
16. IL-13 receptor-targeted cytotoxin cancer therapy leads to complete eradication of tumors with the aid of phagocytic cells in nude mice model of human cancer.
Kawakami K; Kawakami M; Puri RK
J Immunol; 2002 Dec; 169(12):7119-26. PubMed ID: 12471149
[TBL] [Abstract][Full Text] [Related]
17. Gene transfer of interleukin 13 receptor alpha2 chain dramatically enhances the antitumor effect of IL-13 receptor-targeted cytotoxin in human prostate cancer xenografts.
Kawakami K; Husain SR; Bright RK; Puri RK
Cancer Gene Ther; 2001 Nov; 8(11):861-8. PubMed ID: 11773976
[TBL] [Abstract][Full Text] [Related]
18. Evidence that IL-13R alpha2 chain in human glioma cells is responsible for the antitumor activity mediated by receptor-directed cytotoxin therapy.
Kawakami K; Kioi M; Liu Q; Kawakami M; Puri RK
J Immunother; 2005; 28(3):193-202. PubMed ID: 15838375
[TBL] [Abstract][Full Text] [Related]
19. Targeting glioblastoma multiforme with an IL-13/diphtheria toxin fusion protein in vitro and in vivo in nude mice.
Li C; Hall WA; Jin N; Todhunter DA; Panoskaltsis-Mortari A; Vallera DA
Protein Eng; 2002 May; 15(5):419-27. PubMed ID: 12034862
[TBL] [Abstract][Full Text] [Related]
20. Development of a recombinant interleukin-4-Pseudomonas exotoxin for therapy of glioblastoma.
Puri RK
Toxicol Pathol; 1999; 27(1):53-7. PubMed ID: 10367674
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
